Articles related to PSYCHEDELICS

In this meta-analysis including 340 patients across six clinical trials, ECT was more effective than ketamine in treating depression. There were no identified differences between the groups in terms of cognition, memory, or serious adverse events.

In this study involving 452 patients with diagnoses of MDD, GAD, and PTSD, IM ketamine reduced depression by 38% and anxiety by 50%, with persistence over 7 months of maintenance therapy.

In treatment-resistant depression, two studies found that COMP360 psilocybin therapy reduced depression and one study reported that using precision medicine for ketamine dosing might decrease the high efficacy-low effectiveness gap.

Incidences of dizziness, dissociation, increased blood pressure, nausea, vertigo, and sedation were highest in week 1 of treatment and the majority are mild or moderate in severity.

SI, sadness, and anxiety symptoms could all be effectively treated with ketamine. The high rates of response and remission in population samples of TRD were comparable to those for interventional therapies. Racemic ketamine infusion as the main treatment for SI requires randomized controlled trials and comparative efficacy studies with other therapies.

In this double-blind randomized clinical trial with 93 participants, the percentage of heavy drinking days during 32 weeks of follow-up was significantly lower in the psilocybin group than in the diphenhydramine group and was accompanied by a decrease in daily alcohol consumption.